Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Deficient activation of CD95 (APO-1/Fas)-mediated apoptosis: a potential factor of multidrug resistance in human renal cell carcinoma.

British journal of cancer - 1 Jun 2000

Ramp U, Dejosez M, Mahotka C, Czarnotta B, Kalinski T, Wenzel M, Lorenz I, Müller M, Krammer P, Gabbert H E, Gerharz C D

Abstract excerpt

The pronounced resistance of human renal cell carcinoma (RCC) to anticancer-induced apoptosis has primarily been related to the expression of P-glycoprotein and effective drug detoxification mechanisms. Because the CD95 system has recently been identified as a key mediator of anticancer drug-induced apoptosis, we analysed the contribution of the CD95 system to chemotherapy-induced apoptosis in four newly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Renal Cell
Share to Drug Resistance, Multiple

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to fas Receptor

Share to Flow Cytometry

Share to Genes, p53

Share to Kidney Neoplasms

Share to Ligands

Source

Open in PubMed Open full text

Identifiers

PMID: 10839301
DOI: 10.1054/bjoc.2000.1155
PMCID: PMC2363218

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Deficient activation of CD95 (APO-1/Fas)-mediated apoptosis: a potential factor of multidrug resistance in human renal cell carcinoma.PMID 10839301Read ↗

Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan.Semantic proximity Read ↗

Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types.Semantic proximity Read ↗

Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.Semantic proximity Read ↗

p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer DrugsSemantic proximity Read ↗

Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment.Semantic proximity Read ↗

The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptosis in response to antimetabolites.Semantic proximity Read ↗

A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs.Semantic proximity Read ↗

Cisplatin Resistance in an Ovarian Carcinoma Is Associated With a Defect in Programmed Cell Death Control Through XIAP RegulationSemantic proximity Read ↗

Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies.Semantic proximity Read ↗

MDM-2 antagonists induce p53-dependent cell cycle arrest but not cell death in renal cancer cell lines.Semantic proximity Read ↗

Role of p53 in cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity.Semantic proximity Read ↗

Necrotic concentrations of cisplatin activate the apoptotic machinery but inhibit effector caspases and interfere with the execution of apoptosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.